This week we've had EyesOn clinical data and approvals for therapies in hematology and neurology. Check out the news onVertex's gene therapy approval for patients as young as 2-years old, Orca's allogeneic cell therapies approval for GVHD, and Ipsen's neurotoxin Phase 3 data showing efficacy in both episodic and chronic migraines.

This week’s Pharma Phriday (April 24, 2026) covers major AI platform launches and enterprise partnerships, showing AI is expanding beyond drug discovery into wider roles. Clinical trials in respiratory, haematology, and neurology had mixed results, while regulators approved products in vaccines, immunology, oncology, and infectious disease. The industry saw notable consolidation with several multi-billion dollar acquisitions in gene therapy, regenerative medicine, and biosimi